-
1.发明公开公开(公告)号：US20240277825A1
公开(公告)日：2024-08-22
申请号：US18291147
申请日：2022-07-20
发明人： Leander GRODE
CPC分类号： A61K39/04 , A61P35/00 , A61K2039/522 , A61K2039/523 , A61K2039/585 , A61K2039/80
摘要： The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of bladder carcinoma, particularly in the second-line treatment of non-muscle-invasive bladder carcinoma.
-
2.发明授权公开(公告)号：US12016911B2
公开(公告)日：2024-06-25
申请号：US18510369
申请日：2023-11-15
申请人： NantCell, Inc.
发明人： Patrick Soon-Shiong
CPC分类号： A61K39/04 , A61K35/15 , A61K39/001119 , A61K39/00114 , A61K39/39 , A61K2039/515 , A61K2039/585
摘要： Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
-
公开(公告)号：US11992516B2
公开(公告)日：2024-05-28
申请号：US18045572
申请日：2022-10-11
发明人： Bai Liu , Peter Rhode , Wenxin Xu , Hing C. Wong
IPC分类号： A61K39/395 , A61K38/17 , A61K38/20 , A61K47/64 , A61P35/00 , A61K39/04 , C07K14/35 , C07K14/54 , C07K14/715 , C07K16/28 , C07K16/32
CPC分类号： A61K38/2086 , A61K38/1793 , A61K39/39558 , A61K47/6425 , A61P35/00 , A61K39/04 , C07K14/35 , C07K14/5443 , C07K14/7155 , C07K16/2818 , C07K16/2827 , C07K16/2887 , C07K16/2896 , C07K16/32 , C07K2317/732 , C07K2319/30 , C07K2319/32 , A61K38/2086 , A61K2300/00
摘要： The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
-
公开(公告)号：US11970709B2
公开(公告)日：2024-04-30
申请号：US17587376
申请日：2022-01-28
发明人： Sarah C. Gilbert , Adrian V S Hill , Matthew G. Cottingham , Matthew Dicks , Susan J. Morris , Alexander Douglas
IPC分类号： A61K39/00 , A61K35/761 , A61K39/12 , A61K39/145 , A61K39/235 , A61P31/16 , C12N15/86 , C12N15/861 , A61K39/04 , A61K39/21 , A61P31/06
CPC分类号： C12N15/861 , A61K35/761 , A61K39/12 , A61K39/145 , A61K39/235 , A61P31/16 , C12N15/86 , C12N15/8613 , A61K39/00 , A61K39/04 , A61K39/21 , A61P31/06 , C12N2710/10044 , C12N2710/10343 , Y02A50/30
摘要： The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orfl, E4Orf2 and E4Orf3 coding regions from AdY25.
-
公开(公告)号：US20240123055A1
公开(公告)日：2024-04-18
申请号：US18380479
申请日：2023-10-16
IPC分类号： A61K39/215 , A61K39/015 , A61K39/04 , A61K39/085 , A61K39/145 , A61K39/21 , A61P31/04 , A61P31/12 , A61P31/16 , C07K14/005 , C07K16/08 , C07K16/12 , C07K16/20 , C08G69/10 , C12N5/16 , C12N7/00
CPC分类号： A61K39/215 , A61K39/015 , A61K39/04 , A61K39/085 , A61K39/145 , A61K39/21 , A61P31/04 , A61P31/12 , A61P31/16 , C07K14/005 , C07K16/08 , C07K16/12 , C07K16/205 , C08G69/10 , C12N5/16 , C12N7/00 , A61K2039/55544 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2770/20022 , C12N2770/20034 , C12N2770/20071
摘要： The invention relates to compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences and to method for treating and preventing an infection in animals and mammals such as humans and antibodies.
-
6.发明公开公开(公告)号：US20240082377A1
公开(公告)日：2024-03-14
申请号：US18510369
申请日：2023-11-15
申请人： NantCell, Inc.
发明人： Patrick Soon-Shiong
CPC分类号： A61K39/04 , A61K35/15 , A61K39/001119 , A61K39/00114 , A61K39/39 , A61K2039/515 , A61K2039/585
摘要： Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
-
公开(公告)号：US20240050552A1
公开(公告)日：2024-02-15
申请号：US18366915
申请日：2023-08-08
IPC分类号： A61K39/145 , A61K39/39 , A61K39/09 , A61K39/104 , A61K39/04 , A61K39/112 , A61K39/085 , A61P31/16
CPC分类号： A61K39/145 , A61K39/39 , A61K39/092 , A61K39/104 , A61K39/04 , A61K39/0283 , A61K39/0275 , A61K39/085 , A61P31/16 , A61K2039/70
摘要： The invention is directed to immunogenic compositions and method of treatment comprising a peptide or nucleic acid that encodes the peptide that induces an immune response in a mammal that is protective against infection by one or more pathogens. The peptide sequence contains multiple epitopes, wherein at least one epitope is a composite epitope which is a combination of two or more conserved epitopes of the pathogen wherein the amino acid sequence of the composite is not an amino acid sequence of the pathogen. In addition, the invention is directed to vaccines comprising the peptide or nucleic acid that encodes the peptide for treating and preventing an infection in mammals such as animals and humans.
-
公开(公告)号：US20240033338A1
公开(公告)日：2024-02-01
申请号：US18021258
申请日：2021-08-12
发明人： Bum Joon Kim , Byoung Jun Kim , Jaehun Oh , Hyejun Seo
CPC分类号： A61K39/04 , A61K39/39 , A61P31/06 , A61K2039/55561
摘要： An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.
-
公开(公告)号：US20240024451A1
公开(公告)日：2024-01-25
申请号：US18018759
申请日：2021-07-30
发明人： Romain Micol , Valerie Duval
CPC分类号： A61K39/12 , C07K14/5434 , C12N15/113 , A61K39/04 , A61K39/0011 , A61P31/14 , A61K48/005 , A61K2039/53
摘要： Provided is a composition comprising a first mRNA construct comprising a first open reading frame (ORF), wherein the first ORF encodes an antigen; wherein the first ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least a first organ protection sequence (OPS), and wherein the first OPS comprises at least two micro-RNA (miRNA) target sequences, wherein each of the at least two miRNA target sequences are optimised to hybridise with a corresponding miRNA sequence. Also provided are further compositions comprising mRNA constructs comprising an ORF and an OPS wherein the ORF encodes a proinflammatory cytokine, and methods including one or both of these compositions for the treatment and prevention of disease such as pathogenic disease.
-
公开(公告)号：US20230330202A1
公开(公告)日：2023-10-19
申请号：US18314024
申请日：2023-05-08
CPC分类号： A61K39/04 , G01N33/505 , A61K2039/5154
摘要： The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.
-
-
-
-
-
-
-
-
-
搜索结果
1322 条记录 (耗时 0.032 秒)
